Preparation and in vitro characterization of paclitaxel-loaded injectable microspheres

Asian Journal of Pharmaceutics

Volumn 4, Issue 3, 2010, Pages 205-211

  Hiremath, Jagadeesh ^a   Kusum Devi, V ^b  

^a East West College of Pharmacy   (India)

^b AL AMEEN COLLEGE OF PHARMACY   (India)

Author keywords

Cancer; injectable; microspheres; paclitaxel

Indexed keywords

MICROSPHERE; PACLITAXEL; PHOSPHATE BUFFERED SALINE; POLYCAPROLACTONE; SOLVENT;

ARTICLE; BREAST CANCER; CELL STRAIN MCF 7; CRYSTALLIZATION; CYTOTOXICITY; DIFFERENTIAL SCANNING CALORIMETRY; EVAPORATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPE; X RAY DIFFRACTION;

EID: 78149364451     PISSN: 09738398     EISSN: 1998409X     Source Type: Journal    
DOI: 10.4103/0973-8398.72119     Document Type: Article

References (17)

1. Harpet E, Dang W, Lapidus RG, Garver RI. Enhanced efficacy of a novel controlled release paclitaxel formulation (paclimer delivery system) for local-regional therapy of lung cancer tumor nodules in mice. Clin Cancer Res 1999;5:4242-8.
2. Johnston SR. Ovarian cancer: Review of the national institute for clinical excellence (NICE) guidance recommendations. Cancer Invest 2004;22:730-42.
3. Watatani M, Ueda K, Daito K, Azumi T, Hirai T, Yamato M, et al. Clinical experience of weekly paclitaxel based treatment as preoperative chemotherapy for patients with primary breast cancer. Breast Cancer 2004;11:187-93.
4. Tarr BD, Yalkowsky SH. A new parenteral vehicle for the administration of some poorly soluble anti-cancer drugs. J Parenter Sci Technol 1987;41:31-3.
5. Swindell CS, Krauss NE. Biologically active taxol analogues with deleted A-ring side chain substituent and variable. J Med Chem 1991; 34:1176.
6. nd ed. New York: CRC Publishers; 1995. p. 237-54.
7. Wang YM, Sato H, Horikoshi I. In vitro and in vivo evaluation of taxol release from poly (lactic-co-glycolic acid) microspheres containing isopropyl myristate and degradation of the microspheres. J Control Release 1997;49:157-66.
8. Paradis R, Page M. New active paclitaxel amino acids derivatives with improved water solubility. Anticancer Res 1998;18:2711-6. (Pubitemid 28386570)
9. Zili Z, Sfar S, Fessi H. Preparation and characterization of poly caprolactone nanoparticles containing griseofulvin. Int J Pharm 2005;294:261-7.
10. Hiremath JG, Kusum Devi V, Kshama Devi, Domb AJ. Biodegradable Poly (sebacic acid-co-ricinoleic-ester anhydride) tamoxifen citrate implants: Preparation and in vitro characterization. J J Appl Polymer Sci 2007;107:2745-54.
11. Jeong JC, Lee J, Cho K. Effects of crystalline microstructure on drug release behavior of polycaprolactone microspheres. J Control Release 2003;92:249-58.
12. Elkharraz K, Faisant N, Guse C, Siepmann F, Yegin BA, Oger JM. Paclitaxelloaded microparticles and implants for the treatment of brain cancer: Preparation and physical characterization. Int J Pharm 2006;137:127-36.
13. Mu L, Feng SS. Fabrication, characterization and in vitro release of paclitaxel (Taxol®) loaded poly (lactic-co-glycolic acid) microspheres prepared by spray drying technique with lipid/cholesterol emulsifiers. J Control Release 2001;76:239-54.
14. Dubernet C. Thermo analysis of microspheres. Theor Chim Acta 1995;248:259-69.
15. Liggins RT, D'Amours S, Demetrick JS, Machan LS, Burt HM. Paclitaxel loaded poly(l-lactic acid) microspheres for the prevention of intraperitoneal carcinomatosis after a surgical repair and tumor cell spill. Biomaterials 2000;19:1959-69.
16. Miglietta A, Cavalli R, Bocca C, Gabriel L, Gasco M. Cellular uptake and cytotoxicity of solid lipid nanospheres (SLN) incorporating doxorubicin or paclitaxel. Int J Pharm 2000;210:61-7.
17. Park EK, Kim SY, Lee SB, Lee YM. Folate-conjugated methoxy poly (ethylene glycol)/poly (caprolactone) amphiphilic block copolymeric micelles for tumor-targeted drug delivery. J Control Release 2005;109:158-68.